Zealand Pharma: first patient picked for phase III trial
(CercleFinance.com) - A first patient with short bowel syndrome will soon start treatment with glepaglutide as Zealand Pharma kicks off its Phase 3 trial.
The Copenhagen-based biotech company has enrolled the first patient in a global Phase 3 trial evaluating the potential of glepaglutide as a novel short bowel syndrome treatment.
The Phase 3 trial seeks to demonstrate efficacy and safety of once- and twice-weekly subcutaneous injections in patients on parenteral support, the firm said.
129 patients will be enrolled at approximately 40 highly dedicated investigational sites across the United States, Canada and Europe.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Copenhagen-based biotech company has enrolled the first patient in a global Phase 3 trial evaluating the potential of glepaglutide as a novel short bowel syndrome treatment.
The Phase 3 trial seeks to demonstrate efficacy and safety of once- and twice-weekly subcutaneous injections in patients on parenteral support, the firm said.
129 patients will be enrolled at approximately 40 highly dedicated investigational sites across the United States, Canada and Europe.
Copyright (c) 2018 CercleFinance.com. All rights reserved.